Late toxicity comparison of alkylating‐based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro‐EWING99‐R1 in France

In Euro‐EWING99‐R1 randomized trial, cyclophosphamide was shown to be noninferior to ifosfamide in the consolidation of standard‐risk Ewing sarcoma (SR‐EWS) after a common induction with VIDE (vincristine‐ifosfamide‐doxorubicin‐etoposide). We present the results of the late effects analysis of VAC (...

Descripción completa

Detalles Bibliográficos
Autores principales: Corvest, Victoria, Marec‐Bérard, Perrine, Lervat, Cyril, Pacquement, Hélène, Toulmonde, Maud, Gentet, Jean‐Claude, Laurence, Valérie, Cleirec, Morgane, Mansuy, Ludovic, Bompas, Emmanuelle, Castex, Marie‐Pierre, Taque, Sophie, Filhon, Bruno, Tabone, Marie‐Dominique, Verité, Cécile, Entz‐Werle, Natacha, Saumet, Laure, Guimard, Gregory, Pondrom, Morgane, Chevreau, Christine, Flandrin, Jennifer, Duranteau, Lise, Rousset‐Jablonski, Christine, Brugières, Laurence, Jimenez, Marta, Le Deley, Marie‐Cécile, Gaspar, Nathalie, Fresneau, Brice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
CANCER THERAPY AND PREVENTION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092329/
https://www.ncbi.nlm.nih.gov/pubmed/36250317
http://dx.doi.org/10.1002/ijc.34326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092329/
https://www.ncbi.nlm.nih.gov/pubmed/36250317
http://dx.doi.org/10.1002/ijc.34326

Ejemplares similares